Involvement of PKR and RNase L in translational control and induction of apoptosis after Hepatitis C polyprotein expression from a Vaccinia virus recombinant

BACKGROUND: Hepatitis C virus (HCV) infection is of growing concern in public health with around 350 million chronically infected individuals worldwide. Although the IFN-α/rivabirin is the only approved therapy with 10–30% clinical efficacy, the protective molecular mechanism involved during the treatment is still unknown. To analyze the effect of HCV polyprotein expression on the antiviral response of the host, we developed a novel vaccinia virus (VV)-based delivery system (VT7-HCV7.9) where structural and nonstructural (except part of NS5B) proteins of HCV ORF from genotype 1b are efficiently expressed and produced, and timely regulated in mammalian cell lines. RESULTS: Regulated transcript production and viral polypeptide processing was demonstrated in various cell lines infected with the recombinant VT7-HCV7.9, indicating that the cellular and viral proteolytic machineries are functional within these cells. The inducible expression of the HCV polyprotein by VV inhibits the synthesis of both host and viral proteins over the time and also induces apoptosis in HeLa and HepG2-infected cells. These effects occur accompanying with the phosphorylation of the translation initiation factor eIF-2α. In cells co-infected with VT7-HCV7.9 and a recombinant VV expressing the dominant negative eIF-2α-S51A mutant in the presence of the inductor isopropyl-thiogalactoside (IPTG), protein synthesis is rescued. The IFN-inducible protein kinase PKR is responsible for the translational block, as demonstrated with PKR-/- and PKR+/+ cell lines. However, apoptosis induced by VT7-HCV7.9 is mediated by the RNase L pathway, in a PKR-independent manner. CONCLUSION: These findings demonstrate the antiviral relevance of the proteins induced by interferon, PKR and RNase L during expression from a VV recombinant of the HCV polyprotein in human cell lines. HCV polyprotein expression caused a severe cytopathological effect in human cells as a result of inhibition of protein synthesis and apoptosis induction, triggered by the activation of the IFN-induced enzymes PKR and RNase L systems. Thus, the virus-cell system described here highlights the relevance of the IFN system as a protective mechanism against HCV infection

Leveraging electronic healthcare record standards and semantic web technologies for the identification of patient cohorts

Introduction The secondary use of Electronic Healthcare Records (EHRs) often requires the identification of patient cohorts. In this context, an important problem is the heterogeneity of clinical data sources, which can be overcome with the combined use of standardized information models, Virtual Health Records, and semantic technologies, since each of them contributes to solving aspects related to the semantic interoperability of EHR data. Our main objective is to develop methods allowing for a direct use of EHR data for the identification of patient cohorts leveraging current EHR standards and semantic web technologies. Materials and Methods We propose to take advantage of the best features of working with EHR standards and ontologies. Our proposal is based on our previous results and experience working with both technological infrastructures. Our main principle is to perform each activity at the abstraction level with the most appropriate technology available. This means that part of the processing will be performed using archetypes (i.e., data level) and the rest using ontologies (i.e., knowledge level). Our approach will start working with EHR data in proprietary format, which will be first normalized and elaborated using EHR standards and then transformed into a semantic representation, which will be exploited by automated reasoning. Results We have applied our approach to protocols for colorectal cancer screening. The results comprise the archetypes, ontologies and datasets developed for the standardization and semantic analysis of EHR data. Anonymized real data has been used and the patients have been successfully classified by the risk of developing colorectal cancer. Conclusion This work provides new insights in how archetypes and ontologies can be effectively combined for EHR-driven phenotyping. The methodological approach can be applied to other problems provided that suitable archetypes, ontologies and classification rules can be designed.This work was supported by the Ministerio de Economia y Competitividad and the FEDER program through grants TIN2010-21388-C01 and TIN2010-21388-C02. MCLG was supported by the Fundacion Seneca through grant 15555/FPI/2010.Fernández-Breis, JT.; Maldonado Segura, JA.; Marcos, M.; Legaz-García, MDC.; Moner Cano, D.; Torres-Sospedra, J.; Esteban-Gil, A.... (2013). Leveraging electronic healthcare record standards and semantic web technologies for the identification of patient cohorts. Journal of the American Medical Informatics Association. 20(E2):288-296. https://doi.org/10.1136/amiajnl-2013-001923S28829620E2Cuggia, M., Besana, P., & Glasspool, D. (2011). Comparing semi-automatic systems for recruitment of patients to clinical trials. International Journal of Medical Informatics, 80(6), 371-388. doi:10.1016/j.ijmedinf.2011.02.003Sujansky, W. (2001). Heterogeneous Database Integration in Biomedicine. Journal of Biomedical Informatics, 34(4), 285-298. doi:10.1006/jbin.2001.1024Schadow G Russler DC Mead CN . Integrating medical information and knowledge in the HL7 RIM. Proceedings of the AMIA Symposium, 2000:764–8.Johnson PD Tu SW Musen MA . A virtual medical record for guideline-based decision support. Proceedings of the AMIA 2001 Annual Symposium, 294–8.German, E., Leibowitz, A., & Shahar, Y. (2009). An architecture for linking medical decision-support applications to clinical databases and its evaluation. Journal of Biomedical Informatics, 42(2), 203-218. doi:10.1016/j.jbi.2008.10.007Peleg, M., Keren, S., & Denekamp, Y. (2008). Mapping computerized clinical guidelines to electronic medical records: Knowledge-data ontological mapper (KDOM). Journal of Biomedical Informatics, 41(1), 180-201. doi:10.1016/j.jbi.2007.05.003Maldonado, J. A., Costa, C. M., Moner, D., Menárguez-Tortosa, M., Boscá, D., Miñarro Giménez, J. A., … Robles, M. (2012). Using the ResearchEHR platform to facilitate the practical application of the EHR standards. Journal of Biomedical Informatics, 45(4), 746-762. doi:10.1016/j.jbi.2011.11.004Parker CG Rocha RA Campbell JR . Detailed clinical models for sharable, executable guidelines. Stud Health Technol Inform 2004;107:145–8.Clinical Information Modeling Initiative. http://informatics.mayo.edu/CIMI/index.php/Main_Page (accessed Jun 2013).W3C, OWL2 Web Ontology Language. http://www.w3.org/TR/owl2-overview/ (accessed Jun 2013).European Commission. Semantic interoperability for better health and safer healthcare. Deployment and research roadmap for Europe. ISBN-13: 978-92-79-11139-6, 2009.SemanticHealthNet. http://www.semantichealthnet.eu/ (accessed Jun 2013).Martínez-Costa, C., Menárguez-Tortosa, M., Fernández-Breis, J. T., & Maldonado, J. A. (2009). A model-driven approach for representing clinical archetypes for Semantic Web environments. Journal of Biomedical Informatics, 42(1), 150-164. doi:10.1016/j.jbi.2008.05.005Iqbal AM . An OWL-DL ontology for the HL7 reference information model. Toward useful services for elderly and people with disabilities Berlin: Springer, 2011:168–75.Tao, C., Jiang, G., Oniki, T. A., Freimuth, R. R., Zhu, Q., Sharma, D., … Chute, C. G. (2012). A semantic-web oriented representation of the clinical element model for secondary use of electronic health records data. Journal of the American Medical Informatics Association, 20(3), 554-562. doi:10.1136/amiajnl-2012-001326Heymans, S., McKennirey, M., & Phillips, J. (2011). Semantic validation of the use of SNOMED CT in HL7 clinical documents. Journal of Biomedical Semantics, 2(1), 2. doi:10.1186/2041-1480-2-2Menárguez-Tortosa, M., & Fernández-Breis, J. T. (2013). OWL-based reasoning methods for validating archetypes. Journal of Biomedical Informatics, 46(2), 304-317. doi:10.1016/j.jbi.2012.11.009Lezcano, L., Sicilia, M.-A., & Rodríguez-Solano, C. (2011). Integrating reasoning and clinical archetypes using OWL ontologies and SWRL rules. Journal of Biomedical Informatics, 44(2), 343-353. doi:10.1016/j.jbi.2010.11.005Tao C Wongsuphasawat K Clark K . Towards event sequence representation, reasoning and visualization for EHR data. Proceedings of the 2nd ACM SIGHIT International Health Informatics Symposium (IHI'12). New York, NY, USA: ACM:801–6.Bodenreider O . Biomedical ontologies in action: role in knowledge management, data integration and decision support. IMIA Yearbook of Medical Informatics 2008;67–79.Beale T . Archetypes. Constraint-based domain models for future-proof information systems. http://www.openehr.org/files/publications/archetypes/archetypes_beale_web_2000.pdfSNOMED-CT. http://www.ihtsdo.org/snomed-ct/ (accessed Jun 2013).UMLS Terminology Services. https://uts.nlm.nih.gov/home.html (accessed Jun 2013).The openEHR Foundation, openEHR Clinical Knowledge Manager. http://www.openehr.org/knowledge/ (accessed Jun 2013).Maldonado, J. A., Moner, D., Boscá, D., Fernández-Breis, J. T., Angulo, C., & Robles, M. (2009). LinkEHR-Ed: A multi-reference model archetype editor based on formal semantics. International Journal of Medical Informatics, 78(8), 559-570. doi:10.1016/j.ijmedinf.2009.03.006SAXON XSLT and XQuery processor. http://saxon.sourceforge.net/ (accessed Jun 2013).NCBO Bioportal. http://bioportal.bioontology.org/ (accessed Jun 2013).The Protégé Ontology Editor and Knowledge Acquisition System. http://protege.stanford.edu/ (accessed Jun 2013).Semantic Web Integration Tool. http://sele.inf.um.es/swit (accessed Jun 2013).Hermit Reasoner. http://www.hermit-reasoner.com/ (accessed Jun 2013).The OWLAPI. http://owlapi.sourceforge.net/ (accessed Jun 2013).Institute for Health Metrics and Evaluation. Global Burden of Disease. http://www.healthmetricsandevaluation.org/gbd (accessed Jun 2013).Segnan N Patnick J von Karsa L . European guidelines for quality assurance in colorectal cancer screening and diagnosis 2010. First Edition. European Union. ISBN 978-92-79-16435-4.W3C. XQuery 1.0: An XML Query Language. http://www.w3.org/TR/xquery/ (accessed Jun 2013).DL Query. http://protegewiki.stanford.edu/wiki/DL_Query (accessed Jun 2013).SPARQL Query Language for RDF. http://www.w3.org/TR/rdf-sparql-query/ (accessed Jun 2013).Semantic Web Rule Language. http://www.w3.org/Submission/SWRL/ (accessed Jun 2013).Marcos, M., Maldonado, J. A., Martínez-Salvador, B., Boscá, D., & Robles, M. (2013). Interoperability of clinical decision-support systems and electronic health records using archetypes: A case study in clinical trial eligibility. Journal of Biomedical Informatics, 46(4), 676-689. doi:10.1016/j.jbi.2013.05.004Marcos, M., Maldonado, J. A., Martínez-Salvador, B., Moner, D., Boscá, D., & Robles, M. (2011). An Archetype-Based Solution for the Interoperability of Computerised Guidelines and Electronic Health Records. Lecture Notes in Computer Science, 276-285. doi:10.1007/978-3-642-22218-4_35MobiGuide: Guiding patients anytime everywhere. http://www.mobiguide-project.eu/ (accessed Jun 2013).EURECA: Enabling information re-Use by linking clinical RE search and Care. http://eurecaproject.eu/ (accessed Jun 2013).Rea, S., Pathak, J., Savova, G., Oniki, T. A., Westberg, L., Beebe, C. E., … Chute, C. G. (2012). Building a robust, scalable and standards-driven infrastructure for secondary use of EHR data: The SHARPn project. Journal of Biomedical Informatics, 45(4), 763-771. doi:10.1016/j.jbi.2012.01.009Clinical Element Models. http://informatics.mayo.edu/sharp/index.php/CEMS (accessed Jun 2013)

The Chemotherapeutic Drug 5-Fluorouracil Promotes PKR-Mediated Apoptosis in a p53- Independent Manner in Colon and Breast Cancer Cells

The chemotherapeutic drug 5-FU is widely used in the treatment of a range of cancers, but resistance to the drug remains a major clinical problem. Since defects in the mediators of apoptosis may account for chemo-resistance, the identification of new targets involved in 5-FU-induced apoptosis is of main clinical interest. We have identified the ds-RNA-dependent protein kinase (PKR) as a key molecular target of 5-FU involved in apoptosis induction in human colon and breast cancer cell lines. PKR distribution and activation, apoptosis induction and cytotoxic effects were analyzed during 5-FU and 5-FU/IFNα treatment in several colon and breast cancer cell lines with different p53 status. PKR protein was activated by 5-FU treatment in a p53-independent manner, inducing phosphorylation of the protein synthesis translation initiation factor eIF-2α and cell death by apoptosis. Furthermore, PKR interference promoted a decreased response to 5-FU treatment and those cells were not affected by the synergistic antitumor activity of 5-FU/IFNα combination. These results, taken together, provide evidence that PKR is a key molecular target of 5-FU with potential relevance in the clinical use of this drug

Mucosal Immune Defence Gene Polymorphisms as Relevant Players in the Pathogenesis of IgA Vasculitis?

ITGAM–ITGAX (rs11150612, rs11574637), VAV3 rs17019602, CARD9 rs4077515, DEFA (rs2738048, rs10086568), and HORMAD2 rs2412971 are mucosal immune defence polymorphisms, that have an impact on IgA production, described as risk loci for IgA nephropathy (IgAN). Since IgAN and Immunoglobulin-A vasculitis (IgAV) share molecular mechanisms, with the aberrant deposit of IgA1 being the main pathophysiologic feature of both entities, we assessed the potential influence of the seven abovementioned polymorphisms on IgAV pathogenesis. These seven variants were genotyped in 381 Caucasian IgAV patients and 997 matched healthy controls. No statistically significant differences were observed in the genotype and allele frequencies of these seven polymorphisms when the whole cohort of IgAV patients and those with nephritis were compared to controls. Similar genotype and allele frequencies of all polymorphisms were disclosed when IgAV patients were stratified according to the age at disease onset or the presence/absence of gastrointestinal or renal manifestations. Likewise, no ITGAM–ITGAX and DEFA haplotype differences were observed when the whole cohort of IgAV patients, along with those with nephritis and controls, as well as IgAV patients, stratified according to the abovementioned clinical characteristics, were compared. Our results suggest that mucosal immune defence polymorphisms do not represent novel genetic risk factors for IgAV pathogenesis

¿La evaluación evoluciona? Una experiencia de coevaluación en ABP

Desde hace 8 años, el grado de Ingeniería Multimedia imparte el 4º curso utilizando Aprendizaje Basado en Proyectos (ABP) e integrando a todas las asignaturas en él. El programa ha tenido mucho éxito, pero siempre ha acusado un problema, la evaluación. Al tratarse de un trabajo en grupo altamente colaborativo, que integra a todas las asignaturas del curso y que durante los dos semestres trabaja en un único gran proyecto, es muy difícil discernir el trabajo real realizado por cada componente del equipo, produciéndose descompensaciones o incluso malas prácticas. Durante años, se ha tratado de adoptar medidas para paliar esta situación, pero persisten algunas disfunciones. Para solucionarlo, hemos diseñado e implantado una metodología de coevaluación, alineada con la gestión del programa ABP y que persigue dos objetivos: procurar un reparto de nota asociado con el esfuerzo individual realizado, basado en información objetiva y cuantificable, junto con una evaluación formativa y sumativa justa; y desarrollar las habilidades blandas imprescindibles hoy en día en entornos de trabajo colaborativos. En este artículo presentamos la herramienta de coevaluación desarrollada, la valoración realizada sobre la herramienta por las/os participantes en la experiencia y exalumnos de años anteriores, y los resultados obtenidos hasta la fecha.For the last 8 years, the Multimedia Engineering degree has been teaching the 4th year using Project Based Learning (PBL) and integrating all the subjects in it. The program has been very successful, but there has always been one problem: assessment. As it is a highly collaborative group work, integrating all the subjects of the course and working on a single large project during the two semesters, it is very difficult to discern the real work done by each member, causing imbalances or even malpractice. For years, we have tried to adopt measures to mitigate this situation, but without any positive results. To solve this problem, we have designed and implemented a co-evaluation methodology, aligned with the PBL program management, which has two objectives: to ensure a distribution of points associated with the individual effort, based on objective and measurable information, together with a fair formative and summative evaluation; and to develop the soft skills that are essential in current collaborative work environments. In this article we present the co-evaluation tool developed, the assessment made of the tool by the participants in the experience and alumni from previous years, and the results obtained to date.El presente trabajo ha contado con una ayuda del Programa de Redes de investigación en docencia universitaria del Instituto de Ciencias de la Educación de la Universidad de Alicante (convocatoria 2021-22). Ref.: 5490, Diseño y desarrollo de una metodología y plataforma TIC para coevaluación en ABP

Population-based colorectal cancer screening programmes using a faecal immunochemical test:Should faecal haemoglobin cut-offs differ by age and sex?

Abstract Background The Basque Colorectal Cancer Screening Programme has both high participation rate and high compliance rate of colonoscopy after a positive faecal occult blood test (FIT). Although, colorectal cancer (CRC) screening with biannual (FIT) has shown to reduce CRC mortality, the ultimate effectiveness of the screening programmes depends on the accuracy of FIT and post-FIT colonoscopy, and thus, harms related to false results might not be underestimated. Current CRC screening programmes use a single faecal haemoglobin concentration (f-Hb) cut-off for colonoscopy referral for both sexes and all ages. We aimed to determine optimum f-Hb cut-offs by sex and age without compromising neoplasia detection and interval cancer proportion. Methods Prospective cohort study using a single-sample faecal immunochemical test (FIT) on 444,582 invited average-risk subjects aged 50–69 years. A result was considered positive at ≥20 μg Hb/g faeces. Outcome measures were analysed by sex and age for a wide range of f-Hb cut-offs. Results We analysed 17,387 positive participants in the programme who underwent colonoscopy. Participation rate was 66.5%. Men had a positivity rate for f-Hb of 8.3% and women 4.8% (p < 0.0001). The detection rate for advanced neoplasia (cancer plus advanced adenoma) was 44.0‰ for men and 15.9‰ for women (p < 0.0001). The number of colonoscopies required decreased in both sexes and all age groups through increasing the f-Hb cut-off. However, the loss in CRC detection increased by up to 28.1% in men and 22.9% in women. CRC missed were generally at early stages (Stage I-II: from 70.2% in men to 66.3% in women). Conclusions This study provides detailed outcomes in men and women of different ages at a range of f-Hb cut-offs. We found differences in positivity rates, neoplasia detection rate, number needed to screen, and interval cancers in men and women and in younger and older groups. However, there are factors other than sex and age to consider when consideration is given to setting the f-Hb cut-off

Impact of the first wave of the SARS-CoV-2 pandemic on the outcome of neurosurgical patients: A nationwide study in Spain

Objective To assess the effect of the first wave of the SARS-CoV-2 pandemic on the outcome of neurosurgical patients in Spain. Settings The initial flood of COVID-19 patients overwhelmed an unprepared healthcare system. Different measures were taken to deal with this overburden. The effect of these measures on neurosurgical patients, as well as the effect of COVID-19 itself, has not been thoroughly studied. Participants This was a multicentre, nationwide, observational retrospective study of patients who underwent any neurosurgical operation from March to July 2020. Interventions An exploratory factorial analysis was performed to select the most relevant variables of the sample. Primary and secondary outcome measures Univariate and multivariate analyses were performed to identify independent predictors of mortality and postoperative SARS-CoV-2 infection. Results Sixteen hospitals registered 1677 operated patients. The overall mortality was 6.4%, and 2.9% (44 patients) suffered a perioperative SARS-CoV-2 infection. Of those infections, 24 were diagnosed postoperatively. Age (OR 1.05), perioperative SARS-CoV-2 infection (OR 4.7), community COVID-19 incidence (cases/10 5 people/week) (OR 1.006), postoperative neurological worsening (OR 5.9), postoperative need for airway support (OR 5.38), ASA grade =3 (OR 2.5) and preoperative GCS 3-8 (OR 2.82) were independently associated with mortality. For SARS-CoV-2 postoperative infection, screening swab test <72 hours preoperatively (OR 0.76), community COVID-19 incidence (cases/10 5 people/week) (OR 1.011), preoperative cognitive impairment (OR 2.784), postoperative sepsis (OR 3.807) and an absence of postoperative complications (OR 0.188) were independently associated. Conclusions Perioperative SARS-CoV-2 infection in neurosurgical patients was associated with an increase in mortality by almost fivefold. Community COVID-19 incidence (cases/10 5 people/week) was a statistically independent predictor of mortality. Trial registration number CEIM 20/217

CIBERER : Spanish national network for research on rare diseases: A highly productive collaborative initiative

Altres ajuts: Instituto de Salud Carlos III (ISCIII); Ministerio de Ciencia e Innovación.CIBER (Center for Biomedical Network Research; Centro de Investigación Biomédica En Red) is a public national consortium created in 2006 under the umbrella of the Spanish National Institute of Health Carlos III (ISCIII). This innovative research structure comprises 11 different specific areas dedicated to the main public health priorities in the National Health System. CIBERER, the thematic area of CIBER focused on rare diseases (RDs) currently consists of 75 research groups belonging to universities, research centers, and hospitals of the entire country. CIBERER's mission is to be a center prioritizing and favoring collaboration and cooperation between biomedical and clinical research groups, with special emphasis on the aspects of genetic, molecular, biochemical, and cellular research of RDs. This research is the basis for providing new tools for the diagnosis and therapy of low-prevalence diseases, in line with the International Rare Diseases Research Consortium (IRDiRC) objectives, thus favoring translational research between the scientific environment of the laboratory and the clinical setting of health centers. In this article, we intend to review CIBERER's 15-year journey and summarize the main results obtained in terms of internationalization, scientific production, contributions toward the discovery of new therapies and novel genes associated to diseases, cooperation with patients' associations and many other topics related to RD research

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

In 2008 we published the first set of guidelines for standardizing research in autophagy. Since then, research on this topic has continued to accelerate, and many new scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Accordingly, it is important to update these guidelines for monitoring autophagy in different organisms. Various reviews have described the range of assays that have been used for this purpose. Nevertheless, there continues to be confusion regarding acceptable methods to measure autophagy, especially in multicellular eukaryotes. For example, a key point that needs to be emphasized is that there is a difference between measurements that monitor the numbers or volume of autophagic elements (e.g., autophagosomes or autolysosomes) at any stage of the autophagic process versus those that measure fl ux through the autophagy pathway (i.e., the complete process including the amount and rate of cargo sequestered and degraded). In particular, a block in macroautophagy that results in autophagosome accumulation must be differentiated from stimuli that increase autophagic activity, defi ned as increased autophagy induction coupled with increased delivery to, and degradation within, lysosomes (inmost higher eukaryotes and some protists such as Dictyostelium ) or the vacuole (in plants and fungi). In other words, it is especially important that investigators new to the fi eld understand that the appearance of more autophagosomes does not necessarily equate with more autophagy. In fact, in many cases, autophagosomes accumulate because of a block in trafficking to lysosomes without a concomitant change in autophagosome biogenesis, whereas an increase in autolysosomes may reflect a reduction in degradative activity. It is worth emphasizing here that lysosomal digestion is a stage of autophagy and evaluating its competence is a crucial part of the evaluation of autophagic flux, or complete autophagy. Here, we present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes. These guidelines are not meant to be a formulaic set of rules, because the appropriate assays depend in part on the question being asked and the system being used. In addition, we emphasize that no individual assay is guaranteed to be the most appropriate one in every situation, and we strongly recommend the use of multiple assays to monitor autophagy. Along these lines, because of the potential for pleiotropic effects due to blocking autophagy through genetic manipulation it is imperative to delete or knock down more than one autophagy-related gene. In addition, some individual Atg proteins, or groups of proteins, are involved in other cellular pathways so not all Atg proteins can be used as a specific marker for an autophagic process. In these guidelines, we consider these various methods of assessing autophagy and what information can, or cannot, be obtained from them. Finally, by discussing the merits and limits of particular autophagy assays, we hope to encourage technical innovation in the field